Louise China

1.6k citations

30 papers · 782 indexed · 2 hit papers · h-index 13

Co-authors: Alastair O’Brien Derek W. Gilroy Ewan Forrest Nick Freemantle Gavin Wright Stephen Ryder Yiannis Kallis Suvi Härmälä
Topics: Liver Disease and Transplantation (22 papers)Liver Disease Diagnosis and Treatment (21 papers)Drug-Induced Hepatotoxicity and Protection (7 papers)
Cited by: Hepatology Epidemiology Critical Care and Intensive Care Medicine
Journals: New England Journal of MedicineSHILAP Revista de lepidopterologíaBrain
Partner nations: United Kingdom Denmark Spain

In The Last Decade

Louise China

28 papers receiving 771 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Guidelines on the management of ascites in cirrhosis

2020 240 citations Guruprasad P. Aithal, Naaventhan Palaniyappan et al. Gut profile →
A Randomized Trial of Albumin Infusions in Hospitalized Patients with Cirrhosis

2021 194 citations Louise China, Nick Freemantle et al. profile →

Peers

Countries citing papers authored by Louise China

Since Specialization

Citations

This map shows the geographic impact of Louise China's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Louise China with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Louise China more than expected).

Fields of papers citing papers by Louise China

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Louise China. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Louise China. The network helps show where Louise China may publish in the future.

Co-authorship network of co-authors of Louise China

This figure shows the co-authorship network connecting the top 25 collaborators of Louise China. A scholar is included among the top collaborators of Louise China based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Louise China. Louise China is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Targeted albumin infusions in hospitalized patients with cirrhosis receiving terlipressin: A post-hoc analysis of ATTIRE 2025 ·Annals of Hepatology ·Nikolaj Torp,Louise China,Mads Israelsen,Ewan Forrest,Nick Freemantle,Jonel Trebicka,Aleksander Krag,Alastair O’Brien	1
2	Hyperbilirubinemia at hospitalization predicts nosocomial infection in decompensated cirrhosis: Data from ATTIRE trial 2025 ·Hepatology Communications ·(unknown),(unknown),Alexander A. Maini,Louise China,(unknown),(unknown),Subhankar Mukhopadhyay,(unknown),Alastair O’Brien	0
3	Splanchnic vein thrombosis associated with SARS-CoV-2 infection: A VALDIG case–control study 2023 ·JHEP Reports ·Pierre Deltenre,Audrey Payancé,Laure Elkrief,Vincenzo La Mura,Florent Artru,Anna Baiges,Jean‐Paul Cervoni,Louise China,Isabelle Colle,Elise Lemaître,Bogdan Procopeț,(unknown),Christophe Bureau,Odile Goria,Isabelle Ollivier,Alexandre Nuzzo,Pierre‐Emmanuel Rautou,Aurélie Plessier	8
4	Investigating potential confounding by indication when considering the association between proton pump inhibitor use, infection, hepatic encephalopathy and mortality in hospitalised decompensated cirrhosis: a post-hoc analysis of the ATTIRE trial 2023 ·EClinicalMedicine ·Louise China,(unknown),Dominic Crocombe,Ewan Forrest,Yiannis Kallis,Stephen Ryder,Gavin Wright,Nick Freemantle,Alastair O’Brien	8
5	P59 Two-year outcomes of using a stepwise thrombolysis protocol for the management of acute non-malignant portomesenteric thrombosis 2022 ·Abstracts ·(unknown),(unknown),(unknown),(unknown),Jonathan D. King,Louise China,Dominic Yu,David Patch	1
6	Use of non-selective B-blockers is safe in hospitalised decompensated cirrhosis patients and exerts a potential anti-inflammatory effect: data from the ATTIRE trial 2022 ·EClinicalMedicine ·(unknown),Louise China,Ewan Forrest,Yiannis Kallis,Stephen Ryder,Gavin Wright,Nick Freemantle,Alastair O’Brien	6
7	Process and Systems: Unlocking the benefits of the Baveno VI guidance when screening for varices: an audit of clinical practice across London 2022 ·Future Healthcare Journal ·(unknown),(unknown),(unknown),Jonathan D. King,Rawen Kader,(unknown),(unknown),Louise China,James Maurice	0
8	Targeted Albumin Infusions Do Not Improve Systemic Inflammation or Cardiovascular Function in Decompensated Cirrhosis 2022 ·Clinical and Translational Gastroenterology ·Louise China,Natalia Bécares,(unknown),(unknown),Nick Freemantle,Alastair O’Brien	13
9	New cases of Budd-Chiari syndrome and splanchnic vein thrombosis after COVID-19 vaccination-a vascular liver disease group (VALDIG) initiative 2022 ·Journal of Hepatology ·Raoel Maan,Aurélie Plessier,Louise China,David Patch,Anna Baiges,Juan Carlos García‐Pagán,Virginia Hernández–Gea,Marie‐Noëlle Hilleret,(unknown),(unknown),Christophe Bureau,(unknown),Alexandra Heurgué–Berlot,Isabelle Ollivier‐Hourmand,Xavier Causse,(unknown),Mandy N. Lauw,Sarwa Darwish Murad	1
10	Monocyte dysfunction in decompensated cirrhosis is mediated by the prostaglandin E2-EP4 pathway 2021 ·JHEP Reports ·Alexander A. Maini,Natalia Bécares,Louise China,(unknown),Amit Patel,Roel P. H. De Maeyer,Nekisa Zakeri,(unknown),Lucy Ly,Derek W. Gilroy,Alastair O’Brien	7
11	Guidelines on the management of ascites in cirrhosisbreakdown → 2020 ·Gut ·Guruprasad P. Aithal,Naaventhan Palaniyappan,Louise China,Suvi Härmälä,Lucia Macken,Jennifer Ryan,Emilie Wilkes,Kevin Moore,Joanna Leithead,Peter Hayes,Alastair O’Brien,Sumita Verma	240
12	ATTIRE: Albumin to prevent infection in chronic liver failure: an interventional randomised controlled trial 2020 ·Journal of Hepatology ·Louise China,Simon S. Skene,Nicholas Freemantle,Kate Bennett,(unknown),Natalia Bécares,Andrew J. Portal,Yiannis Kallis,Gavin Wright,Derek W. Gilroy,Ewan Forrest,Alastair O’Brien	3
13	PROFIT, a PROspective, randomised placebo controlled feasibility trial of Faecal mIcrobiota Transplantation in cirrhosis: study protocol for a single-blinded trial 2019 ·BMJ Open ·(unknown),Vishal Patel,Simon Goldenberg,Alberto Sánchez‐Fueyo,Louise China,Alastair O’Brien,Clare Flach,Abdel Douiri,Debbie L. Shawcross	21
14	Immune Regulatory Mediators in Plasma from Patients With Acute Decompensation Are Associated With 3-Month Mortality 2019 ·Clinical Gastroenterology and Hepatology ·Natalia Bécares,Suvi Härmälä,Louise China,Romain A. Colas,Alexander A. Maini,(unknown),Simon S. Skene,Zainib Shabir,Jesmond Dalli,Alastair O’Brien	11
15	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for an interventional randomised controlled trial 2018 ·BMJ Open ·Louise China,Simon S. Skene,Kate Bennett,Zainib Shabir,(unknown),(unknown),(unknown),Alexander A. Maini,Natalia Bécares,Derek W. Gilroy,Ewan Forrest,Alastair O’Brien	21
16	Administration of Albumin Solution Increases Serum Levels of Albumin in Patients With Chronic Liver Failure in a Single-Arm Feasibility Trial 2017 ·Clinical Gastroenterology and Hepatology ·Louise China,Simon S. Skene,Zainib Shabir,Alexander A. Maini,Yvonne Sylvestre,Kate Bennett,(unknown),James O’Beirne,Ewan Forrest,(unknown),Stephen Ryder,Gavin Wright,Derek W. Gilroy,Alastair O’Brien	19
17	Albumin Counteracts Immune-Suppressive Effects of Lipid Mediators in Patients With Advanced Liver Disease 2017 ·Clinical Gastroenterology and Hepatology ·Louise China,Alexander A. Maini,Simon S. Skene,Zainib Shabir,Yvonne Sylvestre,Romain A. Colas,Lucy Ly,(unknown),(unknown),Jesmond Dalli,Derek W. Gilroy,Alastair O’Brien	49
18	ATTIRE: Albumin To prevenT Infection in chronic liveR failurE: study protocol for a single-arm feasibility trial 2016 ·BMJ Open ·Louise China,Nicola Muirhead,Simon S. Skene,Zainib Shabir,Roel P. H. De Maeyer,Alexander A. Maini,Derek W. Gilroy,Alastair O’Brien	6
19	OC-050 The Ugib-dops: Improving Training In Gi Bleed Management In The Endoscopy Unit 2014 ·Gut ·Louise China,Gavin Johnson	2
20	Partial sequencing of 5’ non-coding region of 7 HGV strains isolated from different areas of China 1999 ·世界胃肠病学杂志：英文版（电子版） ·(unknown),(unknown),Zhuang zhuang,(unknown),Сонг,Haibo,(unknown),(unknown),(unknown),(unknown),Fujun Yu,(unknown),(unknown),(unknown),Louise China	1

About Louise China

Louise China is a scholar working on Hepatology, Pharmacology and Epidemiology, having authored 30 papers that have together received 782 indexed citations. Recurring topics across this work include Liver Disease and Transplantation (22 papers), Liver Disease Diagnosis and Treatment (21 papers) and Drug-Induced Hepatotoxicity and Protection (7 papers). The work is most often cited by research in Hepatology (515 citations), Epidemiology (448 citations) and Critical Care and Intensive Care Medicine (56 citations). Louise China has collaborated with scholars based in United Kingdom, Denmark and Spain. Frequent co-authors include Alastair O’Brien, Derek W. Gilroy, Ewan Forrest, Nick Freemantle, Gavin Wright, Stephen Ryder, Yiannis Kallis, Suvi Härmälä, Naaventhan Palaniyappan and Joanna Leithead. Their work appears in journals such as New England Journal of Medicine, SHILAP Revista de lepidopterología and Brain.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact